Regional Differences in Serotonin Transporter Occupancy by Escitalopram: An [11C]DASB PK-PD Study.

abstract：:Doxycycline and minocycline are second-generation tetracyclines. They are readily absorbed, distributed throughout the organism as a function of their lipophilicity and eliminated in both the urine and the faeces. The influence of age, renal disease, malnutrition and hyperlipidaemia is reviewed, together with the main...

journal_title：Clinical pharmacokinetics

authors： Saivin S,Houin G

更新日期：1988-12-01 00:00:00

abstract：BACKGROUND AND OBJECTIVES:Currently, the majority of the surgical procedures performed in paediatric hospitals are done on a day care basis, with post-operative pain being managed by caregivers at home. Pain after discharge of these post-operative children has historically been managed with oral codeine in combination ...

journal_title：Clinical pharmacokinetics

authors： Velez de Mendizabal N,Jimenez-Mendez R,Cooke E,Montgomery CJ,Dawes J,Rieder MJ,Aleksa K,Koren G,Jacobo-Cabral CO,Gonzalez-Ramirez R,Castañeda-Hernandez G,Carleton BC

更新日期：2015-10-01 00:00:00

abstract：:Mifepristone is a steroidal antiprogestin and antiglucocorticoid acting at the receptor level. The aromatic dimethylaminophenyl side chain in position 11 of the steroid structure is essential for the antagonistic properties of mifepristone. The pharmacokinetics of mifepristone are characterised by rapid absorption, a ...

journal_title：Clinical pharmacokinetics

authors： Heikinheimo O

更新日期：1997-07-01 00:00:00

abstract：:Antipyrine pharmacokinetics were studied in 6 healthy women before and 2, 8 and 12 weeks after administering the injectable progestagen (progestin), norethisterone (norethindrone) enanthate 200mg intramuscularly. Additionally, antipyrine kinetics in 5 women who had previously used the injectable contraceptive for 8 to...

journal_title：Clinical pharmacokinetics

authors： Joshi JV,Gupta KC,Hazari KT,Gokral J,Pohujani S,Satoskar R

更新日期：1986-03-01 00:00:00

abstract：:Nabumetone is a nonsteroidal anti-inflammatory drug (NSAID) of the 2,6-disubstituted naphthyl-alkanone class. Nabumetone is metabolised to an active metabolite 6-methoxy-2-napthylacetic acid (6-MNA) which is a relatively selective cyclo-oxygenase-2 inhibitor that has anti-inflammatory and analgesic properties. Nabumet...

journal_title：Clinical pharmacokinetics

authors： Davies NM

更新日期：1997-12-01 00:00:00

abstract：BACKGROUND:Fast-acting insulin aspart (faster aspart) is an ultra-fast-acting formulation of insulin aspart (IAsp). This post hoc analysis investigated the pharmacokinetics of faster aspart versus IAsp, measured as free or total IAsp, and the relationship between anti-IAsp antibodies and the pharmacokinetics/pharmacody...

journal_title：Clinical pharmacokinetics

authors： Haahr H,Pieber TR,Mathieu C,Gondolf T,Shiramoto M,Erichsen L,Heise T

更新日期：2019-05-01 00:00:00

abstract：:First-pass elimination takes place when a drug is metabolised between its site of administration and the site of sampling for measurement of drug concentration. Clinically, first-pass metabolism is important when the fraction of the dose administered that escapes metabolism is small and variable. The liver is usually ...

journal_title：Clinical pharmacokinetics

authors： Pond SM,Tozer TN

更新日期：1984-01-01 00:00:00

abstract：INTRODUCTION:In hypo-albuminemia, the extent of albumin binding of a drug decreases. The resulting change in plasma protein binding only rarely leads to clinically relevant changes in unbound drug exposure. Nevertheless, in the critically ill, a tendency to increase dosing of anti-infective therapy is seen in patients ...

journal_title：Clinical pharmacokinetics

authors： T'jollyn H,Vermeulen A,Van Bocxlaer J,Colin P

更新日期：2018-01-01 00:00:00

abstract：:Thienopyridines are inactive prodrugs that are converted in vivo to active metabolites, which irreversibly bind to and inactivate platelet P2Y(12) receptors, and inhibit platelet activation and aggregation. Prasugrel is a third-generation thienopyridine, recently approved for prevention of thrombotic cardiovascular co...

journal_title：Clinical pharmacokinetics

authors： Small DS,Farid NA,Payne CD,Konkoy CS,Jakubowski JA,Winters KJ,Salazar DE

更新日期：2010-12-01 00:00:00

abstract：:The results of research studies conducted to date in vitro and in healthy volunteers are practically all concordant in demonstrating the lack of any kind of interference between famotidine and microsomal oxidative metabolism. The pharmacokinetics (elimination half-life, area under the plasma concentration-time curve, ...

journal_title：Clinical pharmacokinetics

authors： Dal Negro R,Pomari C,Turco P

更新日期：1993-03-01 00:00:00

abstract：:The effects of diabetes mellitus on the pharmacokinetics and pharmacodynamics of drugs have been well described in experimental animal models; however, only minimal data exist for humans and the current knowledge regarding the effects of diabetes on these properties remains unclear. Nevertheless, it has been observed ...

journal_title：Clinical pharmacokinetics

authors： Dostalek M,Akhlaghi F,Puzanovova M

更新日期：2012-08-01 00:00:00

abstract：:Various pharmacokinetic models, both simple and complex, have been developed to describe the way in which the rate of hepatic elimination of drugs depends on hepatic blood flow, hepatic intrinsic clearance and unbound fraction of drug in blood. A model is necessary because it is not possible to measure the average blo...

journal_title：Clinical pharmacokinetics

authors： Morgan DJ,Smallwood RA

更新日期：1990-01-01 00:00:00

abstract：BACKGROUND AND OBJECTIVE:Dalcetrapib, a cholesteryl ester transfer protein (CETP) modulator, is a thioester pro-drug that is rapidly hydrolysed to generate a pharmacologically active thiol. The thiol covalently binds to plasma proteins as mixed disulfides, extensively distributes into plasma lipoprotein fractions, and ...

journal_title：Clinical pharmacokinetics

authors： Phelan M,Anzures-Cabrera J,Carlile DJ,Rowell L,Kuhlmann O,Arold G,Robson R,Bentley D

更新日期：2013-04-01 00:00:00

abstract：:The intracellular pharmacokinetics of the different classes of antimicrobials into surrogate markers of tissue accumulation (alveolar macrophages and/or total alveolar cells collected by means of bronchoalveolar lavage or peripheral white blood cells) was reviewed. The aim of this review was to discuss the clinical im...

journal_title：Clinical pharmacokinetics

authors： Pea F

更新日期：2018-02-01 00:00:00

abstract：:The pharmacokinetics of dothiepin were evaluated in 9 depressed patients following a single oral dose of 75 mg. Blood and plasma concentrations of dothiepin and 2 major metabolites, northiaden and dothiepin S-oxide, were measured by gas chromatography/mass fragmentography. The mean (+/-SD) peak plasma concentrations o...

journal_title：Clinical pharmacokinetics

authors： Maguire KP,Norman TR,McIntyre I,Burrows GD

更新日期：1983-03-01 00:00:00

abstract：:A change in drug clearance with age is considered an important factor in determining the high prevalence of adverse drug reactions associated with prescribing medications for the elderly. Despite this, no general principles have been available to guide drug administration in the elderly, although a substantial body of...

journal_title：Clinical pharmacokinetics

authors： Le Couteur DG,McLean AJ

更新日期：1998-05-01 00:00:00

abstract：:Models of tolerance are commonly derived on empirical grounds, because of lack of knowledge about the mechanism of tolerance or because of the difficulty of appropriately simplifying complex physiological processes. The present study was performed to evaluate the interchangeability of tolerance models used in the lite...

journal_title：Clinical pharmacokinetics

authors： Gårdmark M,Brynne L,Hammarlund-Udenaes M,Karlsson MO

更新日期：1999-02-01 00:00:00

abstract：BACKGROUND:Olmesartan medoxomil (CS-866) is a new orally active angiotensin II receptor antagonist that is highly selective for the AT1 receptor subtype. OBJECTIVE:To develop a population pharmacokinetic model for olmesartan (RNH-6270), the active metabolite of olmesartan medoxomil, in healthy volunteers and hypertens...

journal_title：Clinical pharmacokinetics

authors： Yoshihara K,Gao Y,Shiga H,Wada DR,Hisaoka M

更新日期：2005-01-01 00:00:00

abstract：:Dorzolamide is a carbonic anhydrase inhibitor for topical ophthalmic application. It is used in the treatment of glaucoma to lower the intraocular pressure. After absorption via the cornea and stroma, it inhibits carbonic anhydrase in the ciliary process, which leads to a reduction of aqueous humour production and the...

journal_title：Clinical pharmacokinetics

authors： Martens-Lobenhoffer J,Banditt P

更新日期：2002-01-01 00:00:00

abstract：:Dosage adjustments can be difficult and time-consuming, especially for the non-specialist. The objective of this investigation was to obtain shortcut formulae to calculate dosage adjustments for (i) a drug obeying linear pharmacokinetics (i.e. first order) and given orally, by a continuous infusion or by an intermitte...

journal_title：Clinical pharmacokinetics

authors： Belloto RJ Jr

更新日期：2009-01-01 00:00:00

abstract：OBJECTIVE:Zanamivir, a clinically proven potent and specific inhibitor of influenza A and B neuraminidase, has been approved in some countries for the treatment of influenza and is in late-stage development for the prophylaxis of influenza. This study investigated whether the coadministration of zanamivir and influenza...

journal_title：Clinical pharmacokinetics

authors： Webster A,Boyce M,Edmundson S,Miller I

更新日期：1999-01-01 00:00:00

abstract：BACKGROUND AND OBJECTIVES:Numerous population pharmacokinetic (PK) models of tacrolimus in adult transplant recipients have been published to characterize tacrolimus PK and facilitate dose individualization. This study aimed to (1) investigate clinical determinants influencing tacrolimus PK, and (2) identify areas requ...

journal_title：Clinical pharmacokinetics

authors： Kirubakaran R,Stocker SL,Hennig S,Day RO,Carland JE

更新日期：2020-11-01 00:00:00

abstract：:Antibiotic therapy is one of the main treatments for cystic fibrosis (CF). It aims to eradicate bacteria during early infection, calms down the inflammatory process, and leads to symptom resolution of pulmonary exacerbations. CF can modify both the pharmacokinetic (PK) and pharmacodynamic (PD) profiles of antibiotics,...

journal_title：Clinical pharmacokinetics

authors： Magréault S,Roy C,Launay M,Sermet-Gaudelus I,Jullien V

更新日期：2021-01-24 00:00:00

abstract：BACKGROUND AND OBJECTIVES:Two phase I drug interaction studies were performed with oral enzalutamide, which is approved for the treatment of metastatic castration-resistant prostate cancer (mCRPC). METHODS:A parallel-treatment design (n = 41) was used to evaluate the effects of a strong cytochrome P450 (CYP) 2C8 inhib...

journal_title：Clinical pharmacokinetics

authors： Gibbons JA,de Vries M,Krauwinkel W,Ohtsu Y,Noukens J,van der Walt JS,Mol R,Mordenti J,Ouatas T

更新日期：2015-10-01 00:00:00

abstract：:Peak expiratory flow rate, adverse effects and serum theophylline concentration were measured during treatment of episodes of severe airways obstruction. 174 patients were randomised to target theophylline concentrations of 10 mg/L or 20 mg/L. The recovery of peak flow rate towards normal values was explicable in term...

journal_title：Clinical pharmacokinetics

authors： Holford N,Hashimoto Y,Sheiner LB

更新日期：1993-12-01 00:00:00

abstract：:Low-molecular-weight heparins are anticoagulants used in the treatment of thrombosis. They have effectiveness and safety profiles similar to those of unfractionated heparin but are considered an attractive alternative because of their predictable pharmacokinetic characteristics. In this article, we demonstrate the nee...

journal_title：Clinical pharmacokinetics

authors： Al-Sallami HS,Barras MA,Green B,Duffull SB

更新日期：2010-09-01 00:00:00

abstract：BACKGROUND AND OBJECTIVES:The aim of this study was to investigate the pharmacokinetics, safety, and tolerability of riociguat after single and multiple oral doses of 1 or 2 mg three times daily (tid), and to determine the effect of smoking on riociguat pharmacokinetics in Chinese men. METHODS:In a randomized, double-...

journal_title：Clinical pharmacokinetics

authors： Zhao X,Wang Z,Wang Y,Zhang H,Blode H,Yoshikawa K,Becker C,Unger S,Frey R,Cui Y

更新日期：2016-05-01 00:00:00

abstract：BACKGROUND AND OBJECTIVES:Upadacitinib is a janus kinase (JAK) 1 inhibitor being developed for the treatment of rheumatoid arthritis (RA) and other inflammatory diseases. This work characterized upadacitinib population pharmacokinetics in healthy subjects and RA patients and the effects of covariates on upadacitinib ex...

journal_title：Clinical pharmacokinetics

authors： Klünder B,Mohamed MF,Othman AA

更新日期：2018-08-01 00:00:00

abstract：:Pharmacokinetic parameters of third generation cephalosporins vary widely, requiring different dosage regimens and adjustment methods for each agent. Although their antibacterial spectrum favours their usage in infections caused by aerobic Gram-negative organisms, due to their limited post-antibiotic effect against th...

journal_title：Clinical pharmacokinetics

authors： Yuk-Choi JH,Nightingale CH,Williams TW Jr

更新日期：1992-02-01 00:00:00

abstract：BACKGROUND AND OBJECTIVES:Bosentan is a competitive antagonist on endothelin receptor A and B (ETA and ETB), displacing the endogenous binding partner endothelin-1 (ET-1) from its binding sites. After administration of escalating single doses of 10-750 mg as an intravenous (i.v.) infusion, bosentan showed dose-dependen...

journal_title：Clinical pharmacokinetics

authors： Volz AK,Krause A,Haefeli WE,Dingemanse J,Lehr T

更新日期：2017-12-01 00:00:00